Alexander CJ van Akkooi MD, PhDMelanoma and Soft Tissue Sarcoma Surgeon, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Dr. Alexander van Akkooi is a board-certified surgical oncologist specializing in melanoma and sarcoma and practicing at the Netherlands Cancer Institute – Antoni van Leeuwenhoek (NCI-AVL) in Amsterdam. Dr van Akkooi is the current chairman of the EORTC (European Organization for Research and Treatment of Cancer) Melanoma Group. He is the head of the NCI-AVL Skin Cancer and Melanoma Unit. Dr van Akkooi has published over 150 peer-reviewed papers in high-impact journals, including NEJM, Lancet, Lancet Oncology, Cell, Nature Medicine, among others, and has presented at numerous international meetings. He is a member of the European Society for Medical Oncology, Society for Melanoma Research, and American Society of Clinical Oncology.
Dr. van Akkooi was awarded his medical degree from Erasmus University in Rotterdam. He was a resident in general surgery at Maasstad Ziekenhuis in Rotterdam, and underwent residency training in surgical oncology at NCI-AVL and Erasmus MC Cancer Institute. His PhD was awarded cum laude from Erasmus University.
Dr. van Akkooi is on the Advisory Board of & has received Consultancy Honoraria from Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Sanofi, 4SC. He also reports Research Grants from Amgen, Novartis, Merck-Pfizer which were all paid to NCI-AVL.
Recent Contributions to PracticeUpdate:
- The Potential Development of PD-L1 as a Biomarker in Advanced Melanoma
- An Open-Source Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Melanoma
- Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma
- Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade
- Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or With Nivolumab for Advanced Solid Tumors
- A Systematic Literature Review and Network Meta-Analysis of Effectiveness and Safety Outcomes in Advanced Melanoma
- Updates on T-VEC in the Management of Melanoma
- Dual Checkpoint Blockade in Advanced Melanoma
- Adjuvant Therapy for High-Risk Melanoma
- Neoadjuvant BRAF/MEK Inhibition for Regionally Advanced Melanoma